Pfizer moves forward with once-daily version of weight loss pill after setbacks

Pfizer on Thursday said it will move forward with a once-daily version of its weight loss pill, danuglipron, after it saw "encouraging" data in an ongoing early-stage study.

The company evaluated several once-daily formulations of the drug and identified one with "the most favorable profile" in terms of safety and how the body reacts to the drug. Pfizer said it plans to conduct trials in the second half of the year to identify the ideal dose of the drug. Results are expected in the first quarter of next year, a spokesperson told CNBC.

Danuglipron "has demonstrated good efficacy in a twice-daily formulation, and we believe a once-daily formulation has the potential to have a competitive profile in the oral GLP-1 space," outgoing Pfizer Chief Scientific Officer Dr. Mikael Dolsten said in a release. Notably, the company did not observe any liver safety issues in patients who received once-daily formulations of the drug.

Pfizer is one of several drugmakers racing to win a slice of the market for a highly popular class of weight loss and diabetes drugs called GLP-1 agonists. Some analysts expect the industry to be worth roughly $100 billion by the end of the decade. 

But Pfizer has so far struggled to break into the market.

The pharmaceutical giant in December discontinueda twice-daily version of danuglipron after patients had trouble tolerating the drug in a mid-stage study. At the time, Pfizer said early study data on the once-daily version would "inform a path forward." 

But investors have been pessimistic about the company's potential in the GLP-1 space ever since it scrapped a different once-daily pill in June 2023 due to elevated liver enzymes in patients who received the treatment. Those were among a string of setbacks Pfizer faced last year on top of the rapid decline of its Covid business, which battered its stock. 

Still, Pfizer has other experimental drugs in earlier stages of development, including one for obesity. The company has not disclosed how those treatments will work. 

"Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and several pre-clinical candidates," Dolsten said in the release.

Pfizer also believes GLP-1s are only "scratching the surface of what we will see in obesity," CEO Albert Bourla said during a conference in June. 

Pfizer's danuglipron is a GLP-1 that promotes weight loss in the same way as Novo Nordisk's injection Wegovy and diabetes treatment Ozempic. The drugs mimic a single hormone produced in the gut called GLP-1, which signals to the brain when a person is full.

Injections from Novo Nordisk and Eli Lilly have soared in demand over the last year despite their hefty price tags and limited insurance coverage. 

The pair – along with Pfizer and other drugmakers – have been racing to develop oral versions that are more convenient for patients to take and easier to manufacture, which could help alleviate supply shortages in the U.S. 

Pfizer has previously said it could acquire or partner with a smaller obesity drugmaker. 

Bourla told reporters at a conference in January that it was unlikely the company would buy an obesity treatment in later-stage development, especially as the company focuses on cutting costs. 

But he said Pfizer was looking for potential licensing deals or earlier-stage weight loss drugs. 

Pfizer's update on danuglipron comes days after the company said it is searching for a successor to Dolsten, who will step down after more than 15 years at the drugmaker. Dolsten played a crucial role in developing Pfizer's Covid vaccine.


Related stories
4 days ago - Pfizer moving ahead with plans for once-daily weight loss pill  The HillPfizer moves forward with once-daily version of weight loss pill after setbacks  CNBCCatch me up: Pfizer's GLP-1 pill and FDA powers  AxiosPfizer moves forward with...
4 days ago - Shares of Tesla (TSLA) recouped its losses from the beginning of the year after 11-straight days of gains, only to turn negative after reports of the company pushing back the unveiling of its robotaxi to October. In addition, Elon Musk's...
2 weeks ago - CNBC spoke with 11 current and former Pfizer employees, who asked to remain anonymous, about Pfizer's dizzying climb, rapid decline and turnaround strategy.
3 weeks ago - (Bloomberg) -- Alnylam Pharmaceuticals Inc. shares soared after its drug succeeded in treating a progressive and deadly form of heart disease, potentially opening up a new avenue for the company’s top-selling product. Most Read from...
3 weeks ago - The 2024 Forbes World's Most Influential CMOs List  ForbesForbes Unveils Its Annual World's Most Influential CMOs List  ForbesThe Most Innovative Chief Marketing Officers in 2024  Business InsiderTrailblazing CMOs redefine 2024 marketing...
Other stories
30 minutes ago - The U.K.’s antitrust watchdog has launched a review of a partnership that Microsoft Corp. inked with Inflection AI Inc,. a heavily funded OpenAI rival, earlier this year. The Competition and Markets Authority, or CMA, announced the move...
38 minutes ago - Dow surges by more than 700 points as investors bet on September rate cut  CNNStock market today: Dow, S&P 500 build on records as a retail sales surprise fuels rate cut hopes  Yahoo FinanceUS stocks rise amid rate cut cheer; retail sales...
38 minutes ago - Nvidia’s market cap will soar to $50 trillion—yes, trillion—says early investor in Amazon and Tesla  FortuneJensen Huang's Nvidia could be worth more than current S&P 500 index value in ten years: Report  Hindustan TimesNvidia could reach...
38 minutes ago - Amazon Prime Day causes workplace injuries, Senate probe finds  The Washington PostBernie Sanders says Amazon's warehouse workers get injured at an 'outrageous level' during Prime Day season  FortuneWhen is Amazon Prime Day 2024? Dates,...
38 minutes ago - Andreessen Horowitz founders plan to donate to pro-Trump super PAC  CNBCMarc Andreessen, Ben Horowitz Say They Plan to Donate to Trump PAC  The InformationSilicon Valley’s tech titans line up to donate to Donald Trump  Financial...